D.E. Shaw & Co’s Myovant Sciences Ltd. MYOV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-39,213
| Closed | -$1.06M | – | 5133 |
|
|
2022
Q4 | $1.06M | Sell |
39,213
-2,644
| -6% | -$69.5K | ﹤0.01% | 3403 |
|
|
2022
Q3 | $752K | Buy |
+41,857
| New | +$668K | ﹤0.01% | 3793 |
|
|
2022
Q2 | – | Sell |
-15,725
| Closed | -$209K | – | 5966 |
|
|
2022
Q1 | $209K | Buy |
+15,725
| New | +$211K | ﹤0.01% | 4845 |
|
|
2021
Q1 | – | Sell |
-26,880
| Closed | -$742K | – | 4601 |
|
|
2020
Q4 | $742K | Buy |
+26,880
| New | +$523K | ﹤0.01% | 3205 |
|
|
2019
Q4 | – | Sell |
-18,785
| Closed | -$98K | – | 4233 |
|
|
2019
Q3 | $98K | Buy |
+18,785
| New | +$139K | ﹤0.01% | 3699 |
|
|
2018
Q2 | – | Sell |
-350,000
| Closed | -$7.45M | – | 3948 |
|
|
2018
Q1 | $7.45M | Hold |
350,000
| – | – | 0.01% | 1165 |
|
|
2017
Q4 | $4.42M | Hold |
350,000
| – | – | 0.01% | 1574 |
|
|
2017
Q3 | $5.42M | Hold |
350,000
| – | – | 0.01% | 1320 |
|
|
2017
Q2 | $4.09M | Hold |
350,000
| – | – | 0.01% | 1497 |
|
|
2017
Q1 | $4.11M | Hold |
350,000
| – | – | 0.01% | 1414 |
|
|
2016
Q4 | $4.35M | Buy |
+350,000
| New | +$4.06M | 0.01% | 1437 |
|
Other funds holding MYOV
D.E. Shaw & Co's MYOV Position: Q1 2023 in Review
D.E. Shaw & Co sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 39,213 shares — an estimated $1.06M sold.
D.E. Shaw & Co first reported a position in MYOV in Q4 2016 and held it in 11 quarters. The position peaked at $7.45M in Q1 2018. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.
- D.E. Shaw & Co reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
- D.E. Shaw & Co sold 39,213 Myovant Sciences Ltd. shares in Q1 2023, an estimated $1.06M.
- D.E. Shaw & Co first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 11 quarters.
- D.E. Shaw & Co's Myovant Sciences Ltd. position peaked at $7.45M in Q1 2018.
- 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.
Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.